(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

RECEPTORTAC

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: United States

Quick snapshot

RECEPTORTAC

ST13

US500000090760515

Class

5

Filing

90760515

Registration

6998197

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

14

Latest update

03/07/2023

Trademark type

Combined

Nice classes

5

Filing date

06/08/2021

Registration date

03/07/2023

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

03/07/2023

Last transaction

03/07/2023

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Supplemental Register

Filing basis

Foreign priority

Drawing code

5

Owner type

99

Owner location

Nanjing, Jiangsu Prov., CN

Examiner

BERTRAND, JOSEPH

Law office

M20

Current location

PUBLICATION AND ISSUE SECTION

Mark description

The mark consists of the stylized word "RECEPTORTAC".

Holders and representatives

Holders

Nanjing Boan Biotechnology Co., Ltd.

Representatives

Paulo A. de Almeida PATEL & ALMEIDA, P. C.

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Pharmaceutical preparations for the treatment and prevention of tumor; Pharmaceutical products for the prevention and treatment of cancer; Biological preparations for the treatment of cancer; Pharmaceutical preparations acting on the central nervous system; Biological tissue cultures for medical purposes; immunostimulants; Injectable pharmaceuticals for treatment of immune system related diseases and disorders; Blood substitute for human use; Cellular function activating agents for medical purposes; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis

Publications

History of USPTO decisions and trademark events.

14 publications found

NRCS

NOTICE OF REGISTRATION CONFIRMATION EMAILED

03/07/2023

R.SR

REGISTERED-SUPPLEMENTAL REGISTER

03/07/2023

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

02/02/2023

CNTA

APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER

01/27/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

01/23/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

01/23/2023

ALIE

ASSIGNED TO LIE

01/20/2023

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

11/21/2022

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

05/21/2022

GNRT

NON-FINAL ACTION E-MAILED

05/21/2022

CNRT

NON-FINAL ACTION WRITTEN

05/21/2022

DOCK

ASSIGNED TO EXAMINER

02/25/2022

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

08/28/2021

NWAP

NEW APPLICATION ENTERED

06/11/2021

Continuous trademark protection

Get notified about every new filing that threatens RECEPTORTAC or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.